Cairo – Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) announced that the Egyptian Drug Authority (EDA) decided that its Anvirizam drug for coronavirus (COVID-19) treatment will be sold to the public for EGP 1,260 per each 40-tablet pack.
The EDA also set the public price of the intravenous Remdesivir powder vials for COVID-19 treatment at EGP 680 per vial, according to a statement on Tuesday.
Anviziram contains the active pharmaceutical ingredient Favipiravir, a generic form of the Japanese anti-viral medicine Avigan.
Rameda obtained the EDA’s approval to start manufacturing Remdisivir, an antiviral medication used in treating critical coronavirus cases, in June and the first production is expected to be in September.
It is worth mentioning that in the first quarter of 2020, Rameda logged net profits of EGP 23.76 million, up from EGP 8.33 million in the year-ago period.